NCT05453006 2025-07-10
Isbaar
University of Minnesota
Phase NA Completed
Clinical Trials
6 trialsNCT02759588 2023-01-05
GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
Genelux Corporation
Phase 1/2 Completed
NCT05180851 2022-02-01
YSCH-01
Shanghai Fengxian District Central Hospital
Phase EARLY_PHASE1 Unknown
NCT00423046 2020-01-02
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age
GlaxoSmithKline
Phase 3 Completed
NCT00492544 2018-09-04
Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age
GlaxoSmithKline
Phase 3 Completed
NCT00541970 2018-08-17
Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs
GlaxoSmithKline
Phase 1 Completed